Dabigatran - an exemplar case history demonstrating the need for comprehensive models to optimise the use of new drugs

• Main Authors: Brian eGodman (Author), Rickard eMalmstrom (Author), Eduardo eDiogene (Author), Sisira eJayathissa (Author), Stuart eMcTaggart (Author), Thomas eCars (Author), Christoph eBaumgärtel (Author), Anna eBrzezinska (Author), Anna eBucsics (Author), Stephen eCampbell (Author), Alexander eFinlayson (Author), Jurij eFurst (Author), Kristina eGaruoliene (Author), Iñaki eGutiérrez-Ibarluzea (Author), Krystyna eHviding (Author), Harald eHerholz (Author), Roberta eJoppi (Author), Marija eKalaba (Author), Ott eLaius (Author), Kamila eMalinowska (Author), Hanne B Pedersen (Author), Vanda eMarkovic-Pekovic (Author), Jutta ePiessnegger (Author), Gisbert eSelke (Author), Catherine eSermet (Author), Dominik eTomek (Author), Luka eVoncina (Author), Vera eVlahovic-Palcevski (Author), Janet eWale (Author), Magdelena eWladysiuk (Author), Menno eVan Woerkom (Author), Corinne eZara (Author), Lars L Gustafsson (Author)
• Format: Book
• Published: Frontiers Media S.A., 2014-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (...